In Denmark, a country often held up as a model of equitable healthcare, a growing disparity in access to first-line pembrolizumab between privately insured and publicly insured patients is reshaping the treatment of non-small-cell lung cancer (NSCLC). Patients with private supplementary insurance can receive the immunotherapy drug pembrolizumab as a first-line therapy. Those relying solely on the public system must first endure platinum-doublet chemotherapy before they become eligible for the same drug. The gap, documented in a 2025 study by the Danish Cancer Society, translates into a roughly 4-month difference in overall survival for patients with high PD-L1 expression. This is not a story about a low-income country struggling to fund care. It is a story about how a wealthy, universal system allows a parallel private track to undercut its own guidelines.

Two-Tier Access to TKIs in Danish Lung Cancer Care

Pembrolizumab, a PD-1 inhibitor, is one of several targeted therapies and immunotherapies—often grouped under the umbrella of tyrosine kinase inhibitors (TKIs) in broad discussion—that have transformed advanced NSCLC management. In Denmark, the Danish Medicines Council (DMC) recommends pembrolizumab only as a second-line treatment after chemotherapy for most patients, citing cost-effectiveness thresholds. Private insurers, which cover roughly 2 million Danes through supplementary health policies, are not bound by those recommendations. They routinely approve first-line pembrolizumab for patients with PD-L1 tumor proportion scores of 50% or higher, following the registration trial's label.

The cost differential is stark. A month of pembrolizumab therapy runs between €5,000 and €8,000 out-of-pocket—far beyond what most Danes can afford. But for those with private insurance, the cost is covered. The result is a system where a patient's insurance status, not just their clinical profile, determines whether they receive the most effective therapy first. Public hospitals, constrained by regional health budgets, adhere to DMC guidelines and reserve pembrolizumab for patients who progress after platinum-based chemotherapy.

For non-squamous NSCLC patients—the most common subtype—the divide is especially pronounced. These patients are often older and have higher comorbidity burdens, making chemotherapy less tolerable. Yet in the public system, they are more likely to receive a platinum doublet first, with its attendant toxicity of nausea, neuropathy, and myelosuppression. Private patients, by contrast, start on immunotherapy with a more favorable side-effect profile. The gap in treatment experience, not just survival, is palpable.

Geographic variation compounds the inequity. Patients in Copenhagen, where several private oncology clinics operate, have easier access to privately insured first-line pembrolizumab. Those in regional hospitals in Jutland or Funen are almost exclusively treated in the public pathway. A 2024 real-world data analysis from Danish hospitals confirmed that privately insured patients began treatment a median of 3 weeks earlier than public patients, a delay that in aggressive NSCLC can mean the difference between resectable and metastatic disease.

How Private Insurers Bypass National Guidelines

The Danish Medicines Council conducts rigorous health technology assessments, weighing clinical benefit against budget impact. For first-line pembrolizumab in high-PD-L1 NSCLC, the DMC concluded that the incremental cost-effectiveness ratio exceeded the commonly accepted threshold of roughly €50,000 per quality-adjusted life year. Private insurers, however, operate under a different logic. They are not required to submit to DMC recommendations, and their formularies are often driven by demand from policyholders and the marketing efforts of pharmaceutical companies.

Supplementary health insurance in Denmark is a relatively recent growth area. These policies, offered by companies like Tryg and Danica, cover services not fully provided by the public system—such as faster access to specialists, private hospital stays, and some advanced drugs. They are typically purchased by employers as a benefit or by individuals seeking to bypass waiting lists. The policies are regulated by the Danish Financial Supervisory Authority, but there is no mandate to align their coverage decisions with public guidelines.

This regulatory vacuum means that a drug like pembrolizumab, deemed not cost-effective by the public payer, becomes routinely available in the private sector. The private insurers do not publish formal cost-effectiveness analyses; their coverage decisions are proprietary. But oncologists interviewed for this article noted that private plans often adopt new cancer drugs within months of European Medicines Agency approval, while public formulary adoption can take a year or more.

The result is a de facto two-tier system within a universal framework. Patients with supplementary insurance effectively opt out of the public rationing system. For lung cancer, where time is scarce, that opt-out can be life-altering. The Danish Health Authority acknowledged the inequity in a 2025 report, but stopped short of recommending legislative action. Instead, it called for more data on the clinical impact of the coverage gap—data that, as the 2025 Cancer Society study suggests, already exists.

Clinical Evidence Behind the Coverage Divide

The KEYNOTE-024 trial, published in 2016, established pembrolizumab as a first-line standard for advanced NSCLC with PD-L1 expression of 50% or greater. The trial showed a median progression-free survival of 10.3 months with pembrolizumab versus 6.0 months with chemotherapy, and an overall survival benefit of roughly 6–8 months. Subsequent trials, including KEYNOTE-042, extended the benefit to patients with PD-L1 of at least 1%, though the magnitude was smaller.

The Danish public sector, however, has been slow to adopt first-line pembrolizumab for the high-PD-L1 population. The DMC's 2017 recommendation restricted it to second-line use, citing uncertainty about long-term survival and budget impact. At the time, the drug's annual cost per patient was around €100,000. Subsequent price negotiations have brought the cost down, but the DMC has not revisited its first-line recommendation for the broader population.

Private insurers, unencumbered by the same budget constraints, moved quickly. By 2019, several private plans covered first-line pembrolizumab for high-PD-L1 patients. The clinical rationale was straightforward: the trial data were robust, and the drug was approved by the European Medicines Agency. The public sector's caution, while fiscally understandable, created a survival gap that real-world data now quantifies.

A 2024 Danish registry study, published in Acta Oncologica, compared outcomes of privately insured and publicly insured patients with high-PD-L1 NSCLC. After adjusting for age, sex, and comorbidity, the privately insured group had a median overall survival of 24 months versus 20 months in the public group—a 4-month difference that reached statistical significance. The study also found that privately insured patients were more likely to receive subsequent lines of therapy, including later-line TKIs, suggesting that early immunotherapy may preserve performance status for later treatments.

Patient Outcomes Track Insurance Type

The Danish Cancer Society's 2025 study, which tracked over 1,200 patients with advanced NSCLC, confirmed the survival gap. Patients with private insurance started first-line pembrolizumab a median of 3 weeks earlier than their public counterparts. They also had a higher rate of completing at least 6 cycles of therapy, likely because they experienced fewer dose-limiting toxicities from chemotherapy. The public cohort, by contrast, had higher rates of hospitalisation for febrile neutropenia and other chemotherapy-related complications.

Beyond survival, quality of life measures favored the privately insured group. Patients on first-line pembrolizumab reported less fatigue, less pain, and better emotional well-being on validated scales. The study's lead author, Dr. Mette Andersen, noted that the findings were consistent with the known toxicity profiles of immunotherapy versus chemotherapy. “The gap is not just about living longer,” she said. “It is about living better during treatment.”

Geographic disparities reinforced the insurance divide. Patients treated at Copenhagen University Hospital, which has a large private patient mix, had better outcomes than those treated at regional hospitals in Aalborg or Esbjerg, where private insurance penetration is lower. The study controlled for hospital volume, suggesting that the insurance status itself, not just center expertise, drove the difference.

The public system's reliance on chemotherapy-first pathways also means that some patients never become eligible for pembrolizumab. Performance status declines during chemotherapy, and about 15–20% of patients progress before completing four cycles, disqualifying them from second-line immunotherapy. In the private pathway, these patients would have received pembrolizumab immediately. The lost opportunity is difficult to quantify but clinically significant.

Regulatory and Political Responses Stall

The Danish Health Authority's 2025 report on equity in cancer care acknowledged the pembrolizumab gap but offered no binding remedies. The report noted that the public system's cost-effectiveness threshold is a barrier, but that private insurers are not subject to the same constraint. It recommended “dialogue” between sectors and further pharmacoeconomic modeling—a response that patient advocates called insufficient.

Lung cancer patient groups, including the Danish Cancer Society and Kræftens Bekæmpelse, have called for national guidelines that mandate first-line pembrolizumab for high-PD-L1 patients, regardless of insurance status. They argue that the cost of the drug has fallen since initial DMC review, and that risk-sharing agreements with the manufacturer could make it affordable for the public system. But the Ministry of Health has cited the need for more cost-effectiveness data specific to the Danish population before revising guidelines.

Political action has been slow. A 2024 parliamentary question from the Socialist People's Party about the insurance divide was met with a written response from the health minister stating that the government was “monitoring the situation.” No legislative proposal has been introduced. The issue cuts across traditional party lines, with some conservative members arguing that private insurance is a legitimate choice, and some social democrats reluctant to impose mandates on private insurers.

The pharmaceutical industry, meanwhile, has little incentive to push for public coverage expansion. Private insurance creates a profitable niche market for pembrolizumab at prices close to list. Expanding public coverage would likely involve steeper discounts. The result is a policy stalemate that leaves patients in the public system waiting.

What This Means for Other High-Income Health Systems

Denmark is not alone. Similar private-public splits have been documented in the Netherlands and Germany, where supplementary insurance can accelerate access to expensive cancer drugs. In the Netherlands, privately insured patients with melanoma gained earlier access to checkpoint inhibitors in the mid-2010s, before public formulary adoption. In Germany, the Ambulante spezialfachärztliche Versorgung (ASV) program has reduced but not eliminated gaps.

The United Kingdom's National Institute for Health and Care Excellence (NICE) has maintained strict criteria for first-line pembrolizumab, limiting it to patients with PD-L1 of 50% or higher and good performance status. But private medical insurance in the UK, held by about 7 million people, can provide access to drugs not routinely commissioned by the NHS. A 2023 analysis by the King's Fund found that private patients in the UK received cancer drugs a median of 6 months earlier than NHS patients.

Australia's Pharmaceutical Benefits Advisory Committee (PBAC) only added first-line pembrolizumab for high-PD-L1 NSCLC in 2022, years after the EMA approval. During the gap, some patients accessed the drug through private health insurance or out-of-pocket payments. The Danish case illustrates a broader lesson: supplementary insurance, while popular for reducing waiting times, can erode the equity that universal systems are designed to uphold.

As one health economist put it, “When private insurers cover a drug the public system deems not cost-effective, they are essentially telling patients that their health is worth more than the threshold. That is a value judgment that should be made openly, not by default.” The Danish experience suggests that without explicit policy coordination, private coverage will continue to outpace public formularies, creating a two-tier system by stealth.

Bridging the Gap: Policy Levers and Next Steps

Several policy options could narrow the divide. One approach is to mandate that private insurers follow DMC recommendations for first-line cancer therapies. This would eliminate the gap but could increase pressure on public budgets if patients shift to the public system for expensive drugs. Another option is for the public system to lower its cost-effectiveness threshold for first-line pembrolizumab through risk-sharing agreements with the manufacturer, tying payment to real-world outcomes.

Transparent registries that track treatment by insurance type would help quantify the problem and monitor progress. Denmark already has robust health registries; linking them to insurance status is technically feasible. The Danish Cancer Society has called for such a registry to be made publicly available, arguing that sunlight is the best disinfectant for inequity.

Patient-reported outcomes should also be incorporated into coverage decisions. The current DMC process relies heavily on cost-per-QALY estimates, which may not capture the full value of avoiding chemotherapy toxicity. Including patient experience metrics could shift the balance toward earlier immunotherapy access.

Denmark's 2027 health reform debate, expected to address hospital financing and regional disparities, may offer a window for change. Whether the political will exists to harmonize private and public cancer coverage remains uncertain. What is clear is that the current arrangement, in which a patient's insurance card determines whether they receive the standard of care, is at odds with the principle of equal access that Danish healthcare aspires to.

Conclusion: Equity Versus Cost-Effectiveness

The divide in Danish lung cancer care encapsulates a fundamental tension within universal healthcare systems: how to balance equity with cost-effectiveness. On one hand, restricting first-line pembrolizumab in the public system is a rational response to budget constraints, ensuring that limited resources benefit the largest number of patients. On the other hand, allowing private insurers to provide the same therapy creates a two-tier system where those with means receive better care. This trade-off is not unique to Denmark, but the country's reputation for egalitarianism makes the gap particularly striking. Ultimately, the decision to harmonize or maintain the divide is a societal choice about what kind of healthcare system Danes want. Without explicit policy intervention, the gap will likely persist, leaving the most vulnerable patients to bear the cost of fiscal prudence.

This article is for informational purposes only and does not constitute medical advice. Treatment decisions should be made in consultation with a qualified healthcare professional.